Tauriga Sciences Inc.'s Products and Product Lines Gaining Significant Traction in Asia
April 17 2020 - 9:40AM
InvestorsHub NewsWire
The Company Recently Received a Sizable Purchase Order From
Japan and Continues to Experience Strong Levels of Interest Through
its ALIBABA Portal
NEW YORK, NY -- April 17, 2020 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating Company that
operates through the development, distribution, and licensing of
proprietary products as well as the evaluation of potential
acquisition opportunities and equity investments, today announced
that its products and product lines are gaining significant
traction and acceptance in Asia. Recently, the Company
received a sizable Purchase Order (“PO”) from a Japanese
Supermarket owner (order has been fully paid for) and continues to
experience strong levels of interest from a number of prospective
Asia based customers. Driving this traction, is the
Company’s portal on Alibaba.com (“ALIBABA”), which
provides it with introductions to potential customers of all types
(located throughout Asia).
In other news, the Company has started the process of
translating its packaging into several different languages – to
help enhance existing revenue opportunities. To start,
the Company plans to offer translated versions, into the following
languages: Japanese and Chinese (Mandarin).
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please
visit our corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates to
the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March
18, 2020, the Company announced that it filed a provisional U.S.
patent application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration
agreement with Aegea Biotechnologies Inc. for the co-development of
a rapid, multiplexed, Novel Coronavirus (COVID-19) test with
superior sensitivity and selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full time E-Commerce fulfillment center located in
LaGrangeville, New York.
CONTACT
INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram:
@tauri_gum
Twitter:
@SethMShaw
Corp. Website: www.tauriga.com
E-Commerce
Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024